Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 9.89 is in line with its 1-year average of 9.20, around the middle of its 1-year range (6.34–11.75).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.89.
QUICK RATIO (ACID-TEST)
9.89
QUICK RATIO (ACID-TEST) AVG TTM
N/A
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+195.28%
vs the sector median at left
Eikon Therapeutics, Inc. Common Stock
Market Cap
$409.29M
Quick Ratio (Acid-Test)
9.89
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$409.69M
Quick Ratio (Acid-Test)
2.64
TTM Avg
6.72
3Y Avg
6.86
5Y Avg
10.10
Market Cap
$409.72M
Quick Ratio (Acid-Test)
9.44
TTM Avg
11.90
3Y Avg
14.34
5Y Avg
23.42
Market Cap
$412.91M
Quick Ratio (Acid-Test)
16.52
TTM Avg
13.61
3Y Avg
8.86
5Y Avg
8.86
Market Cap
$405.49M
Quick Ratio (Acid-Test)
1.98
TTM Avg
1.95
3Y Avg
1.91
5Y Avg
2.07
Market Cap
$405.74M
Quick Ratio (Acid-Test)
8.13
TTM Avg
16.34
3Y Avg
21.67
5Y Avg
17.16
Market Cap
$402.01M
Quick Ratio (Acid-Test)
10.64
TTM Avg
18.70
3Y Avg
14.71
5Y Avg
15.03
Market Cap
$401.78M
Quick Ratio (Acid-Test)
3.46
TTM Avg
8.89
3Y Avg
4.63
5Y Avg
3.55
Market Cap
$399.35M
Quick Ratio (Acid-Test)
8.66
TTM Avg
7.11
3Y Avg
5.24
5Y Avg
5.24
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $409.29M | 9.89 | N/A | N/A | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $409.69M | 2.64 | 6.72 | 6.86 | 10.10 |
| Rezolute, Inc. (RZLT)vs › | $409.72M | 9.44 | 11.90 | 14.34 | 23.42 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $412.91M | 16.52 | 13.61 | 8.86 | 8.86 |
| Myriad Genetics, Inc. (MYGN)vs › | $405.49M | 1.98 | 1.95 | 1.91 | 2.07 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $405.74M | 8.13 | 16.34 | 21.67 | 17.16 |
| Neurogene Inc. (NGNE)vs › | $402.01M | 10.64 | 18.70 | 14.71 | 15.03 |
| YD Bio Limited Ordinary Shares (YDES)vs › | $401.78M | 3.46 | 8.89 | 4.63 | 3.55 |
| Carlsmed, Inc. (CARL)vs › | $399.35M | 8.66 | 7.11 | 5.24 | 5.24 |
| Prothena Corporation plc (PRTA)vs › | $417.78M | 25.05 | 8.87 | 10.83 | 12.06 |
Quick Ratio
9.89
Excludes inventory
Current Ratio
9.89
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 9.89 |
| 2026-03-31 | 11.75 |
| 2025-12-31 | 6.34 |
| 2025-09-30 | 8.80 |
